CN106701990B - Detect the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity - Google Patents
Detect the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity Download PDFInfo
- Publication number
- CN106701990B CN106701990B CN201710076508.3A CN201710076508A CN106701990B CN 106701990 B CN106701990 B CN 106701990B CN 201710076508 A CN201710076508 A CN 201710076508A CN 106701990 B CN106701990 B CN 106701990B
- Authority
- CN
- China
- Prior art keywords
- linc00472
- expression
- mouth neoplasm
- reagent
- prognosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of applications of the reagent of long-chain non-coding RNA LINC00472 expression quantity in detection oral cavity tumor tissues, it is used to prepare the prognosis preparation of mouth neoplasm patient, especially prepares the kit of real time fluorescent quantitative detection method prediction mouth neoplasm patient prognosis.Confirm that LncRNA LINC00472 expresses downward in mouth neoplasm tissue by research, mouth neoplasm patient's poor prognosis of the mouth neoplasm patient Bi Gao expression LncRNA LINC00472 of low expression LncRNA LINC00472, therefore, the expression of LncRNA LINC00472 is used for the prognosis prediction of mouth neoplasm patient, strong molecular biology foundation can be provided for the prognosis of mouth neoplasm patient, there is far-reaching clinical meaning and important popularization and application foreground.
Description
Technical field
The invention belongs to oncomolecularbiology fields, and in particular to detection long-chain non-coding RNA LINC00472 expression
Primer, detection reagent and its application of amount.
Background technique
Oral and maxillofacial malignancy is common high-incidence head-neck malignant tumor, is easy to happen metastasic cervical lymph nodes,
Prognosis is poor.Studies have shown that the occurrence and development of this tumour are polygenes participation, multi-step, multistage complex process, wherein
The inactivation of tumor suppressor gene and the activation of oncogene have played crucial effect.
Long-chain non-coding RNAs (long non-coding RNAs, lncRNAs) are that a kind of length is more than 200nt, lacks
The RNAs molecule of special complete open reading frame, nothing or few encoding histone functions.It has recently been demonstrated that lncRNAs
By adjusting the expression of gene extensively in epigenetic, transcription and post-transcriptional level, they take part in biology growing, development,
The regulation of the important vital movement such as aging and death.More and more researches show that the unconventionality expression or afunction of lncRNAs
It is closely related with the occurrence and development of tumour.Some lncRNAs molecules have great importance in terms of the diagnosing and treating of tumour,
And it can be used as tumor prognosis and judge new molecular labeling.Currently, the mankind lncRNAs gene cloned is more than 40,000
It is a, but the Unknown Function of overwhelming majority lncRNA.
We have detected expression of the LINC00472 in clinical Ex vivo Tumor sample, and analyze LINC00472 table
Up to the horizontal correlation with clinical case data.We are after extract RNA in mouth neoplasm and corresponding normal control tissue
By reverse transcription, real-time quantitative PCR has detected the expression of LINC00472, and LINC00472 is in mouth neoplasm as the result is shown
It expresses and lowers in tissue.The method that we then utilize in situ hybridization again is further demonstrated in archive paraffin sample
LINC00472 expresses significant downward in mouth neoplasm, therefore can be used for mouth neoplasm for the detection preparation of LINC00472
Auxiliary diagnosis carries out survivorship curve analysis in conjunction with clinical return visit data and finds that LINC00472 expresses its life span of low patient
The shorter than lncRNA expresses high patient, therefore the prognosis that can be used for mouth neoplasm for the detection preparation of the lncRNA is sentenced
It is disconnected.
Summary of the invention
The object of the present invention is to provide the examinations of long-chain non-coding RNA LINC00472 expression quantity in detection oral cavity tumor tissues
The application of agent, the reagent are used to prepare mouth neoplasm auxiliary diagnosis or outcome prediction preparation, the long-chain non-coding RNA
The sequence of LINC00472 is shown in SEQ NO:1.
The mouth neoplasm auxiliary diagnosis or outcome prediction preparation is existed according to long-chain non-coding RNA LINC00472
Expression in mouth neoplasm carries out auxiliary diagnosis and outcome prediction, and in mouth neoplasm tissue LINC00472 expression is significant
It lowers.
The mouth neoplasm auxiliary diagnosis or outcome prediction preparation is real time fluorescent quantitative detection reagent.
Include in the real time fluorescent quantitative detection reagent
Primer sequence for real time fluorescent quantitative detection LINC00472 expression:
Forward primer: 5 '-GCATCTGTCAACGCTCCTCT-3 ',
Reverse primer: 5 '-CCGCGTTCTTTGTGTGTCTC-3 '.
The real time fluorescent quantitative detection preparation includes:
Reference gene GAPDH Specific PCR primers:
Forward primer 5 '-ACCACAGTCCATGCCATCAC-3 '
Reverse primer 5 '-TCCACCACCCTGTTGCTGTA-3 '.
Also contain in reagent:
(1) the extracted total RNA agents useful for same from mouth neoplasm tissue, including RNA stablizing solution, Trizol reagent, trichlorine
Methane, isopropanol, without enzyme water;
It (2) is cDNA agents useful for same, including reverse transcription buffering by LncRNA LINC00472 reverse transcription by template of total serum IgE
Liquid, triphosphoric acid base deoxynucleotide, RNase inhibitor, MMLV reverse transcriptase and random primer;
(3) by cDNA real-time quantitative PCR agents useful for same, including real time fluorescent quantitative SYBR dyestuff, without enzyme water.
We detect from reverse transcription after extract RNA in mouth neoplasm and normal oral epithelium sample, real time fluorescent quantitative method
The expression of LINC00472, as the result is shown LINC00472 expresses downward in mouth neoplasm tissue.Prompt LINC00472 can make
For the molecular marker of mouth neoplasm prognosis prediction.The present invention provides strong for the auxiliary diagnosis and prognosis prediction of mouth neoplasm
Biology tool, have far-reaching clinical meaning and important popularization and application foreground.
Detailed description of the invention
Fig. 1 is the expression water that LINC00472 in the in vitro sample of mouth neoplasm is detected using the method for real-time fluorescence quantitative PCR
It is flat;
LINC00472 is in the expression in mouth neoplasm (T) than significantly lowering in normal control (N) sample;
Fig. 2 in situ hybridization detects expression of the LINC00472 in mouth neoplasm and normal oral mucosa;
Left figure be normal oral mucosas tissue, right figure be mouth neoplasm tissue, (amplification factor: 200 ×), LINC00472
Expression is lower in mouth neoplasm;
Fig. 3 is the correlation of the expression and patient's prognosis of LINC00472 in mouth neoplasm;
Expresser is good than LINC00472 low expression or not for the highly expressed patient's prognosis of LINC00472, i.e., LINC00472 is low
Expression or the patient not expressed are faster dead.
Specific embodiment
The present invention is further illustrated below in conjunction with specific embodiment, is not intended to limit the present invention.
Embodiment 1, the detection of real time fluorescent quantitative method confirm that LINC00472 expresses downward in mouth neoplasm
1. materials and methods:
9 normal oral mucosas and 9 mouth neoplasm tissue extracted total RNAs, 2 μ g RNA after reverse transcription is at cDNA, into
Row real-time fluorescence quantitative PCR.
Forward primer: 5 '-GCATCTGTCAACGCTCCTCT-3 ',
Reverse primer: 5 '-CCGCGTTCTTTGTGTGTCTC-3 '.
Internal reference house-keeping gene GAPDH Specific PCR primers for control:
Forward primer 5 '-ACCACAGTCCATGCCATCAC-3 '
Reverse primer 5 '-TCCACCACCCTGTTGCTGTA-3 '.
Real-time fluorescence quantitative PCR reaction system
Real-time fluorescence quantitative PCR reaction step
The amplification curve and melting curve of real-time fluorescence quantitative PCR, the expression intensity root of each gene are confirmed after reaction
After CT value (threshold cycle values), reference gene (GAPDH) markization, using group t-test checking computation
P value.
2. result
LncRNA LINC00472 expressed in normal control tissue it is lower, and in mouth neoplasm tissue low expression or
P < 0.001 (Fig. 1) is not expressed
Embodiment 2, expression of the in situ hybridization detection discovery LINC00472 in mouth neoplasm are related to patient's prognosis
1. MATERIALS METHODS
1.1 are used for the oligonucleotide probe of mouth neoplasm and normal control tissue in situ hybridization
Root Ju LINC00472 gene sequencing is designed 3 best oligonucleotides of the best specificity of Crossbreeding parameters and is visited
Needle, in addition, using house-keeping gene GAPDH as positive control.
Oligonucleotide probe in situ hybridization detection LINC00472 expression:
LINC00472 probe 1:5 '-CAAAACTAGGATTCTGTCTTTGAGGCAGAC-3 '
LINC00472 probe 2:5 '-AAGAATGGAAGTGGGAAGAGAGAAAGACTT-3 ';
LINC00472 probe 3:5 '-TAATTCAGGGGTATCCGTCTTAGTTTAGGC-3 '.
Positive control probe (detection house-keeping gene GAPDH):
GAPDH probe 1:5'-CCACTTTACCAGAGTTAAAAGCAGCCCTGG-3'
GAPDH probe 2:5'-GTCAGAGGAGACCACCTGGTGCTCAGTGTA-3'
GAPDH probe 3:5 '-CAGTAGAGGCAGGGATGATGTTCTGGAGAG-3 '.
Oligonucleotide probe is synthesized using chemical synthesis process
1.2 oligonucleotide probe labelling kits and in situ hybridization detection reagent
Dig Oligonucleitide Tailing Kit(2ndGeneration) kit (Roche company), anti-ly
High octyl- horseradish peroxidase complex detection kit (Anti-Digoxigenin-POD, Fab fragments, Roche
Company).Enhance the TSA signal amplifying system (TSA of detection of expression signal in situTMBiotin System, NEL700 kit,
PerkinElmer company).DAB staining kit (Beijing Zhong Shan company).20 × SSC, dextran sulfate (Dextran
Sulphate), deionized formamide (Deionized Formamide), polyadenylic acid (polyadenylic acid, Poly
A), poly deoxyadenylic acid (polydeoxyadenylic acid, Poly dA) is denaturalized the frog essence DNA (denatured of shearing
And sheared salmon spermDNA, ssDNA), yeast transfer RNA (yeast t-RNA, tRNA), DTT, 50 ×
Denhardts ' s solution, PBSbuffer, pepsin K, BSA (bovine serum albumin), triethanolamine (TEA), TNB
Buffer (0.1M Tris-HCl, pH7.5,0.15M NaCL, 0.5%Blocking Reagent), TNT Buffer (0.1M
Tris-HCl, pH7.5,0.15M NaCL, 0.05%Tween 20) acetic anhydride, block reagent (Blocking reagent
Agent, Roche company).
1.3 other main agents and material
Dehydrated alcohol, 90% alcohol, 70% alcohol, 50% alcohol, turpentine oil, distilled water, PBS buffer solution (pH7.2~
7.4, NaCl 137mmol/L, KCl 2.7mmol/L, Na2HPO44.3mmol/L, KH2PO41.4mmol/L);3% methanol-
Hydrogen peroxide solution (80% methanol and the configuration of 30% hydrogen peroxide);0.01mol/L citrate buffer (citrate buffer,
CB, pH6.0 ± 0.1,9ml 0.1M citric acid solution and 41ml 0.1M sodium citrate solution are added interim in 450ml distilled water
With postponing correction work liquid pH value again);0.1% trypsase;Haematoxylin;1% hydrochloride alcohol (1ml concentrated hydrochloric acid+99ml 70%
Alcohol configuration);The dedicated mounting glue of micro-array tissue (PTS Cure Mount II);Dedicated coverslip (480 × 240mm2) customization
In Zhengzhou Glassware Factory.Leica low melting point (58 DEG C) paraffin, domestic beeswax, absolute alcohol, dimethylbenzene, 10% neutral poly
Formaldehyde (0.01mol/L, pH7.4, DEPC distilled water and PBS buffer solution are prepared), haematoxylin, Yihong, neutral mounting natural gum, lid glass
Piece, glass slide.
The label of 1.4 oligonucleotide probes
Oligonucleotide probe label is carried out using 3-tailing DIG Olignucleutide Kit, reaction system is such as
Under.
100pmol oligonucleotide+ddH2O=9 μ l (5 μ of control:control oligonucleutide
l+ddH2O 4μl)
It mixes, is slightly centrifuged.37 DEG C of water-bath 30min add 2ul EDTA (0.2M, pH 8.0) stopped reaction.
It is purified after 1.5 oligonucleotide probes label
In order to increase the purity of label probe, marked probe need to be purified, concrete operations are as follows:
A) cold ethyl alcohol (- 20 DEG C) of+2.5 μ l 4M LiCL+75 μ l of probe reaction mixture (22 μ l) 100%
B) -70 DEG C of precipitatings 60min, or-20 DEG C of 2h.
C) 13.000 × g, 4 DEG C of centrifugation 15min.
D) supernatant is abandoned, with 70% (V/V) ethanol washing that 50 μ l are ice-cold.
E) 4 DEG C of 13.000xg are centrifuged 5min.
F) supernatant, 4 DEG C of dryings of vacuum are abandoned.
G) with the molten probe of aseptic double-distilled water weight.
1.6 histotomies hybridize pre-treatment
A) histotomy of 4 DEG C of preservations is placed in 58 DEG C of roasting piece 30min, melted surface paraffin.
B) dimethylbenzene successively dewaxes 3 × 5min.
C) step ethanol wash, 100% 1 × 5min of the alcohol of 2 × 2min of alcohol → 95% alcohol of 1 × 5min → 70% →
50% 1 × 5min of alcohol → 2 × 3min of DEPC water washing → DEPC-PBS washs 2 × 5min.
D) 300 μ l pepsin K (10 μ g/ml) are added dropwise on slice, 37 DEG C of digestion 20min.
E) it is sliced and washs 1min, stopped reaction into PBS (0.1M PBS+2mg/ml glutamic acid).
F) it is sliced into 0.2N HCL, in 37 DEG C of reaction 20-30min, increases the permeability of tissue.
G) slice fixes 10min, room temperature with 4% paraformaldehyde (0.1M PBS dissolution) afterwards.
H) in order to increase tissue positive intensity for hybridization, acetylation process is carried out to slice.It is sliced into 0.25% acetic anhydride
Buffer I (0.1M triethanolamine), room temperature 10min.
I) 1M PBS washs 2 × 5min.
1.7 tissue prehybridizations and hybridization
A) prehybridization: the prehybridization solution of -20 DEG C of preservations is first placed in 37 DEG C of incubation 60min, and the dosage of prehybridization solution is often to put down
Square 12.5 μ l of cm chips area, parafilm covering of corresponding size is sliced, prehybridization 2 hours in 37 DEG C of wet box.(prehybridization solution
Composition includes: 2XSSC, 10%Dextran sulphate, 1X Denhardt ' s solution, 50mM Phosphate
Buffer (PH 7.0), 50mM DTT, 250 μ l, 100 μ g/ml poly A, 5 μ g/ml poly dA, 250 μ g/ml yeast
T-RNA, 500 μ g/ml ssDNA, 47%Deionized formamide).
B) parafilm is removed, prehybridization solution is got rid of, slice is placed in 5min in 2 × SSC.
C) hybridization reaction: 37 DEG C of hybridized overnights (18-20h).Each slice is added 250 μ l hybridization solutions and is covered with parafilm
Lid.Corresponding probe is added in prehybridization solution just becomes hybridization solution.Hybridization solution is prepared in prehybridization, is placed 37 DEG C of incubations, is made
Probe is completely dissolved in hybridization solution, this experiment is mixed with a plurality of oligonucleotide probe, is matched by each probe 500ng/ml concentration
Probe hybridization solution is made.Digoxin tailing labelling kit label probe concentration calculation foundation: the concentration of each probe by its with
Colour developing is compared when detection reaction when positive quantitative probe and the naked probe of 30 bases of 100pmol marks reaction theory to visit
Needle yield is that two kinds of standards of 900ng carry out the concentration that COMPREHENSIVE CALCULATING goes out label probe.
D) post-hybridization washing, slice immerse 2 × SSC, 10min, throw off parafilm.Successively washed in shake on shaking table, 2 ×
SSC (0.5%SDS), 2 × 15min → 0.25 × SSC (0.5%SDS), 2 × 15min.
Color developing detection is reacted after 1.8 hybridization
A) digoxigenin-probe compound in conjunction with purpose RNA is detected using Anti-Digoxigenin-POD;TSA amplification system
The positive signal of system enhancing in situ hybridization reaction solution reaction, DAB colour developing.
B) slice is gone in TNT buffer, 3 × 5min.
C) TNB is added dropwise and blocks buffer, 300 μ l/TMAs, room temperature, 30min.
D) it does not wash, sucks extra blocking agent, the diluted Anti-Digoxigenin-POD (TBS+0.1% of 1:100
TritonX-100+1% blocking agent), room temperature 4 hours.
E) TNT Buffer (0.1M Tris-HCl, PH7.5,0.15M NaCL, 0.05%Tween 20) washes 3 × 5min.
F) signal is added dropwise on slice and amplifies reagent Biotinyl Tyamid, 300 μ l/TMAs, (Biotinyl Tyramid
Store liquid: Biotinyl Tyramid is dissolved in 0.2ml DMSO, Biotinyl Tyramid working solution: 1 × dilution, 1:50
Dilute Biotinyl Tyramid and store liquid), room temperature 10 minutes.
G) TNT is washed, 3 × 5min.
H) SA-HRP (strepto- avidin-horseradish peroxidase) is added dropwise in slice, 300 μ l/TMAs, room temperature 30min.
I) TNT is washed, 3 × 5min.
J) distilled water washing, 1 × 1min.
K) DAB develops the color, and controls chromogenic reaction under microscope.
L) haematoxylin is redyed,
M) alcohol step is dehydrated, chip drying.
N) the dropwise addition dedicated mounting glue of histotomy, the coverslip cover plate of dimension, what dicing-tape transfer system was equipped with
Crosslinking slice 1min under ultraviolet lamp.
The judgement of 1.9 results and standard
Application Optics microscope is observed under low power and high power lens respectively, looks first at the positive expression of target RNA
The signal positioning intracellular in object observing: it is located at nucleus, cytoplasm or cell membrane.
It is carried out respectively with two kinds of standards of the intensity of the detection rna expression position positive signal and the cell number of positive expression again
Comprehensive score, judgment criteria are as follows: (1) judge according to positive cell dyeing intensity: a. cell dye-free remembers 0 point;B. cell is dyed
Light brown is weakly positive, remembers 1 point;C. cell dyes brown and dyes dark-brown without background coloration or cell and have light brown back
Scape is moderate positive, remembers 2 points;D. cell dyes dark-brown and is strong positive without background coloration, remembers 3 points.(2) according to positive cell
Express number score: the no positive cell expression of a. remembers 0 point;B. positive expression cell number≤25% remembers 1 point;C.25% < is positive thin
Born of the same parents' number < 50% remembers 2 points;D. positive expression cell number >=50% remembers 3 points.
In order to reduce the subjective factor of appraisal result as far as possible, it is respective that You Liangwei pathology expert presses one of above-mentioned standard respectively
Judged and scored, then the two is scored and is multiplied, as a result are as follows: 1. 0 point of person is finally calculated as 0 point, it is believed that feminine gender expression;2. 1 point
1 point is finally calculated as with 2 points of persons, it is believed that weakly positive expression;3. 3 points and 4 points of persons are finally calculated as 2 points, it is believed that moderate positive expression;④
6, which assign to 9 points of persons, is finally calculated as 3 points, it is believed that strong positive expression.
1.10 analyses and statistical software
Statistical analysis is carried out to experimental result using SPSS13.0 statistical software, compares use χ two-by-two2Test or Fisher
Exact test, correlation analysis use Spearmen correlation method;P < 0.05 is that difference is statistically significant.
Survivorship curve analysis uses Kaplan-Meier method and log-rank test;Multi-variables analysis uses Cox ' s
proportional hazards model;P < 0.05 is that difference is statistically significant.
2 results
1) expression of the lncRNA LINC00472 in mouth neoplasm and normal control tissue
LINC00472 has expression (Fig. 2 is left) in normal control tissue, and expresses in most of mouth neoplasm tissue
It is lower or do not express (Fig. 2 right), there is apparent statistical difference (P < 0.05) between the two.
2) Kaplan-Meier survival analysis
We have carried out Effect of follow-up visit by telephone to all 69 mouth neoplasm patients, have inquired their start time in detail, have controlled
Treat situation, whether there is or not recurrence, whether there is or not suffering from other diseases, recurrence and death time etc. again, and register life span and state, and right
The survival analysis that the expression of LINC00472 and the life span of patient and state carry out in mouth neoplasm tissue, discovery
The LINC00472 highly expressed survival of patients time, which expresses patient that is low or not expressing compared with LINC00472, will grow (Fig. 3).Explanation
LINC00472 is a molecular labeling relevant to mouth neoplasm prognosis, which expresses low, patient's poor prognosis.
SEQUENCE LISTING
<110>Central South University
<120>application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity is detected
<130>nothing
<160> 11
<170> PatentIn version 3.3
<210> 1
<211> 9515
<212> RNA
<213>sequence of long-chain non-coding RNA LINC00472
<400> 1
augcgaggcu ggggccgguu gccuaccggc cgcuucucgc cgaggcaguc cagacuuuuc 60
ccccggcggu gcccgcucca agacagcauc ugucaacgcu ccucuucucc ccuccuccuc 120
cugccgggcc gggcuccgcc ggcugcggcc gagaggacgc gggacccggc gcggugagcc 180
caucagcugu caggcgagcg gcgaagcggc uggagggcgg cgagagacac acaaagaacg 240
cggugggcgg cggcggcgaa aggggacggc aacuccuccc cgcgcccgcc ggugccaccg 300
ccggccgugc uuguuccgag gccgcgcaga caaugcggcc gggcucgucc ccgcgugccc 360
cagagugcgg agcgcccgcg cucccccgac cccaacuuga ccgucucccg gcucgcccag 420
cccccucccg ggguaggggc gcccccuccc uccgguggcc ggcgaaggaa gucgguccgc 480
ggccgcagau cccggcaacu ugcgaaccgg gaaaaguuug cggcgccucc gcggggcggc 540
gcgacgcggc ccgccccucg cguccgcggu caucgcgggu gacuuucucg acucgucguc 600
agccggggcc gcagcgcggc cgguggggac ugcggggcgg gccggagucc guccgagggc 660
ucccgcaccu cgggcugcgg auuucaggua cuccacuggg cauuuucucu ucauggagcu 720
uauagcaaca aaaguguuuu acaaaacacc agacauguug gcaucaucuc uuaguugggc 780
cauguggcca gggaacccuu caugaaacca ccucugcagu ccuggagagu ugcuguagaa 840
gaaggaaaag agaggaagac aacacaacac aggaggggau aaguaccucu ggacacaaug 900
gaaguaguag uuguugagca gagggaaagg gauaggagaa ggauguggac ugcagugcug 960
cagugccagg uaauaacuuu gaucauguac cuccuuggcu caggugcugu cucuucuacu 1020
cuccuccuua cuuguacuac cuuauuuagc acuuaauuau auacuuucuu gacucacuuu 1080
gagacacacu gauuaugugg ucugccucaa agacagaauc cuaguuuugg auuuuagcau 1140
uacugaucua uagccuugca ggggcuuaag gauggcagcu gucucucucc cuugggaucu 1200
agcuuuugca aauauugaag ggaagagauu ucuuugaucu uauaggaaua gauccacagu 1260
uccucuccag auuugcuuuu auagagaagu gugugucacc aaaacaaugg agauacgguc 1320
agagaggccc cuacccccag aauuuuaaua uaauuuuacu uucuggggca uuuauucuug 1380
acaaauacuu ucucuccuau cagcucacuu guuccucaca aaaacccuau aagauauuaa 1440
uauuauuaaa cagaccccua ugaagcaccu caagucuuuc ucucuuccca cuuccauucu 1500
ugcacaccuu uugcuagacu agucucugcg uucaucacau cagguuucua aaauaaaagu 1560
ccccuaauaa cuuucuauuu guucucucau cauauugaac cuuuuuugcc uggcuuauaa 1620
gguggccuua aaaccccauu uuccucuaaa cauugucucu guaguucagg aauauggcag 1680
gcucaacacu augcuugagc ccauauugcu ucccucauua gugaugccuc cucucagacc 1740
acccagauuc uacucauucu ucaauuucca gcuucuccuu ggagccuucc cagaucauua 1800
gcuucuuaaa aaucccagcu uucucugaau ucugauggua gcccccguua uuuggacaau 1860
uauguccugg ucuuaaaguc cuaaugggaa aaaaaaguac augauggacu ucauguagag 1920
aagaaagcac uggacugagu uuuaagacag cugcuaagga gcugugugag ccaaaccagg 1980
uuacuuuacc ucucuggauc uauauuugcu gaucuguuaa guggagacaa uugggucaga 2040
uaaucuuggu ggucuuugcu uauucugagg uucuuggaca acuuggccua guucacgugg 2100
gaugggauug aagaucuuac ugaguucuug gauggaaaug ucaguaaugg gcacuuagug 2160
ccuucaggac uuguucuaua cuaucccaga aauuucugau gcuaaacuug gcaauuuuua 2220
aaugucauau uccuuuucuc caaacucuuu aaccacaaga auucagggaa gguuaugggg 2280
ggugacuuag uuaucuggau aauacauauu guggacaaua uagcauuauc cuugggaaug 2340
auuucauauu guugaauaaa uaggaucaac uucuugauaa accuuagucc caagcauuuc 2400
aucuucauug gauaguguua cauaguaaua uauuuauguu uucuuuuaau cauuucauaa 2460
cuuggaaaau acuaacauag ucaaaacucu aggguaggug auacaugagu uucuguagua 2520
aucugguugg agacauguug uaauucugua uauauaugua cauuuauccc augcauguua 2580
ugccuaaacu aagacggaua ccccugaauu aagaggugcu guuauacauu gaccaggcuu 2640
aagaauaucu cuuuaaagug ugucgacauu uaauugaccu uuggaaguuc auucuguuaa 2700
ucauacucaa agugcuaaag cuaugguuga cugcucuggu guuuuuauau ucauucgugc 2760
uuuagcauau aaauucuuca gcauaauugc uacuuauuua gcaagaguuu ccuuuauuug 2820
aaaaugugag uugugcuugu auuuuugugu cuuucuuucu uucuuucuuu uuuuaaacuu 2880
ugcuucaggc uggguagugg uagagguuug aauuaaaaug uuuuccuguc aguaguugua 2940
ugaggugugg cuucuuaauc uagaaguaau ggaaauuucu ugcuuaaaug aagugcacuu 3000
uucuuccugc agaaguuaga acucuuuuag acaagcuuaa cacuucaaaa cuguauaucu 3060
uuaacagaaa cuuuuggaaa uuuuuaaauu ccauuugugu agauuaaaaa uaucaaugcu 3120
aauacuuucu auuaaauaag gauuuaucua uuuucauaaa accucuaauu auauuccuug 3180
aauugcuaug aguagaauuu uguuguaaac acaauauuuu uaaaaaguca aauauauuuu 3240
aaaaaucuua acauuauauu acuauaacuu agagaacagg uguuuacaug uuuaaaauuu 3300
ucuaggccuu aaauuuguga aaucagucuu ucagaaguua uuuuuaauau aguuaucugu 3360
guuacagguu uauaaguuga cauuucaauu uaaaauuuuu ucaauuuaua uuucaaugac 3420
caggaaaaaa uaguuaaacu uauuccuaaa uuuuaauaga aaaauaaaaa accacauagu 3480
uguuaauuuc ugguaauuua ucuugagacu ccaggcaugu uuuuagaaca uuuuuaccuu 3540
aaaagcaauu uugaaauagg gaaauuaaag uuuaaagcag aguuuucacu uuaaugaggu 3600
aauuuuauac uucccagaua gguaggccca uauucaagaa cacucugauc ucuguuuaua 3660
guaaguuuug augccauuau aucauuuacu uauucacgca uuauaagcau aguagauagc 3720
cccauuguca cgaagcuggc auuauuuucu ugucugucau ucaauauugu ccccuuuuuu 3780
uuuucuguuu ucaucauagc cguccuuuuc auuuuauugu agcccugacu cgaaaugaaa 3840
guaaguuuga acucuuaaaa aagaguuccu caaacucuuu uuuaagaaua uacagugaaa 3900
ugucuuaaau aauauuaucu aaauaauacc uaaagaaugc aaaugacuug caaugcugaa 3960
uagucagaca caggauguuc caugcuaagg guagacucau auuuccacuu uauaaaaugu 4020
gguuucagaa aacaaauaga uguguuucuu ccuuaauaau uaguguuuca ggaccaaagu 4080
ugacuaaaua uggaaguuua agauaaaacc cgguuucuua gggaaucuuu cucaguccuu 4140
aguaauucug uagaauugau gauagagugg caacuucaau acacucagua uucuuuucug 4200
uuugaagucu guuuugccau uggaaaaaac uuauuguugu uugaauuugg guauauguau 4260
ucacagaugg uuuacuuuau uuuuauuuug uuuaaacaaa uacuuucaug ucccaaacac 4320
ugagacaugu uucauguccu aaacacuuua uaaauauuag aauauuuaau ccccuuaacu 4380
cuguaguuau aauuaucuuc auuuuacaau ugagaaaacu aagauacgac guuuuauuua 4440
augguaacgc cuuaaguaag gggagaguga uaaguguaag cagaguggaa aacuuaguag 4500
ugcuaaggag caacagaagu augugcaaga guuugggaag augugucugc uuggaaagga 4560
ucagggacuc agcugggauc agucuuaaag agcaacaugu ccucauuccu caauuuuaag 4620
ccuuugggcu cuagaaguaa agggcaaacu uagaggaggc acuccucagg uuucagcugc 4680
cuguuccggc cuggugaggu ggcuguacug gcucaugugu uucucauagg gcuacaugag 4740
ccuuuauguc uuaccuccuc cucauuucuu ggcugacucc ugcuuuuuug gaggguuuaa 4800
cuucucucuc agcuagaagg uuaggcauug caaauaccag uggauaauuu uuuucuuagc 4860
uuuaacccca gcccauuuca acccccucuu ugcccuuugu auauucuuuu gaaaauauga 4920
uccaguagug uuuaugaaug uguguugugu aaaauuuaga gauugauguu aaacaacaga 4980
auuaaaggac aaagcugucu uuuuuguugg aauuggggau gggagagcag cucaaagugg 5040
gaaauaugga gaaaggagag acauugugga aaagaagaga uaaauugagg ggaaaaaaag 5100
aggaugaaaa aaugaagaga gagaauuacu gaugugcuuc acacccacac cuccucucca 5160
acuucacagu aacagaggca augucacuau cuuuuaccug acaagugcuu uaccagggag 5220
uugugccugg caucguggga guggaaaauu uuucccuuuu gcauuuugag acuugggugu 5280
gcugcuuuaa gaugccacug guaucuaagu aauguuuguu uauacuggau auuuuucucu 5340
guagccuuug uggauuggac uuauaauaua aacaauauug uuagcagaac ugcagguacu 5400
cuauugcuau guuuauuuua uuaguuaaaa aacuaccaga gcccuaggac uucugagcac 5460
auuuagaaaa uaccagaggc aauuuuaaga cuagcauuag aaagaaagaa aagaauaaga 5520
auaaaacuaa gacuugcaua ccuuagaauc cuaaccaaug uggugauuuu uaaaaauuaa 5580
uguuucagag acucuaaauu aggguaguug guuucaucaa uuacauuuuu uaaguuaaua 5640
uaaagugcuu uuguauguaa auucucuuaa uagauaauuu agguaaaaug aaaguguggc 5700
auuuuuuguu ccauagaaug uaaaacuaac gucagaauaa gaauucuuuu gggaauuuag 5760
gauuuuuuug augcuucuca aaucaucugu aaugacuuuu auuuauagaa aagguagauu 5820
auucauuagu uuuuaugaaa aacacucagu uuaaauagcc ggguauggug gcgcauggcu 5880
guagucccag cuacucagga ggcugggcac gagaauugcu ugaaccugug aggcagaggu 5940
ugcagugagc caagaucgca ccacugcacu ccagccuggu ccagagugag auuccgucuc 6000
gaacaaaaca aaacaaaaau auugagcuaa ucuaaauggu aaaaaucuag auuugaagaa 6060
auuuauuuua aaauaguugu ucauuuguca aauagaaaag uaugaucuua gcagguuugg 6120
uuagaucccu aucugaaaca aaguaaacua aagauguuuu ucuugaucaa ugcauagcaa 6180
uaacugcugu ucaaacaugu gaggaaucac caguaaauug ggggauagaa agcaggaaaa 6240
ggagcuuuuu ucucuuauuu uuuuucauuu aucaguuuuu cccauuuguc cauccuuucc 6300
uauaaucaug gaaauuuuua uuuuuuacac uccucucccc auuuuuuuau ccuagauugc 6360
caccacacca agguuuucua gaguuaggca gaaagagaac cugggccuag augcuaaugg 6420
aaacuauccc augcuuucuc agacucucuu uccuccccag agacaagagg agcaaaacag 6480
gaguugaugg cucauugcug uugcuucugu ggcugcccug uuugguugac cugagcuuuu 6540
uuuaaaaacc uccacucuug acgcuuaacu cuaugaauaa aauuagggcc agucacacug 6600
uauuuucauc aucaguuauc ccuagugauu caaauuuagc acaaaccugc ugugaguaca 6660
uauuaauuag gugaauacag uagaaugcaa ucauaacaug agucuuuuaa uaacuauucu 6720
uuguuugauu uuuauuuuag aaguuugaag uuauuuuguu gaaaaucuag aaaaucuuua 6780
ugugagcaac ugagguucgg guagcccaca acaguuuaaa ucaaacauua acuugcagua 6840
aaacacuacu gaaagugucu uugauuuuga ggugcagaga gcuguuucaa guuaaguugc 6900
uauauuaguc uguucucaug cugcuaauaa agacauaccu gcaaccgggc aauuuauuaa 6960
aaaaaaaaag agguuuaauu gacugacagu uccacauggc uggggaggcc ucaccgucau 7020
ggugaaagag caagggaugu cuuacauggu ggcaggcaag aaguuugugc agaggaacuc 7080
cuguuuauaa aaccaccaga ucucaugaga cuuacucacu accaggagaa caggaugcgg 7140
gaaaccaccu cggugauuca guuaucugca ccuggcccca cccuugacac auguugauua 7200
uuacaauuca aggugagauu uggguaggua cacagccaaa ccauaucagc ugcccauucu 7260
ccugugcagu gacauaaagg ucugauaacc ugauuuaaag cuuggacucu aagauuuuuu 7320
uuuuucuuuu uuugagucag guuaucucug ucgcucaagc uggaguucag uggcaugaac 7380
agggcucauu gcagccucaa ccuuccaggu ucaagugauu cucuugccuc aaccuccuga 7440
guaucugggg cuacaggcau gugccaccgu gccaggcuaa uauuuuuauu uuuauuuuug 7500
uaaagauggg gucucacuuc ugggcucaag caaucuuucc ucagccuccc aaagugcugg 7560
gauuauaggu gcgagccacu gcacccugcu guaaagaauu ucauaucccu guuuucggug 7620
ugcuguguca cuguuugcca uggguaaagg uauaugaauc ucuuuuauuu ugcugcuugc 7680
aacccaauuc ccaugccaaa cccaauuugu auccaaacaa acaauauugg agacaaguuc 7740
uucuauagaa agcuucauaa gccaguuacu gacuacugug ucuguaaaua uacucaaacu 7800
auuuuguagu cuugcuauuu uaaaaaaugu gugggugugg gaagugaugu ugaaugaauu 7860
caggguaauu ggugguucuu uguauuagga aaacucacua guuaagggaa gucuguuuuc 7920
augauucaug uauguuuaac uuaaaaaaaa auucuuccau ccuucucucc aguuuccacu 7980
cuaccucaua aauucaagua augaaggaau uuaaauaaua gaauuuuaua acugaaagga 8040
uuuuggagag aaucuauuaa cccuccuacu acaguugagg aaauagaugu ccagugaggu 8100
caaaugagau cauguagcua guuuaaaaac ccaaauaaca uuuuaguagu uuguuuccau 8160
uaguaaacac uguucuguuu gauuugcccu aacauguuca uaaucagagu cauaauaagg 8220
aaaaaucacu aauaugugug ugguacuuuc uugugcauac cucagucacu ucucaaaaga 8280
ggucuguaag gugucgguau ccugguuucc auucagggag agaacagucu augagccuaa 8340
gagaccuguc ugugccaguc acuaucagaa cagucuaaug cuaugugucu uccuaccuug 8400
gcaaaagcau uggcuggucu cuggacaguu cucauagacc acaggauugg gcagggggga 8460
gccacaucuu cauguuaggg cucuaaccug uaccaauuau uaacuguugu cucuauuuca 8520
ucauuucuua aagggaaaaa aaagcacuuu uuaaagagca ugagauuuua aauuuuucaa 8580
aagaaggaug cuggaucauu auaaguaagg cauguuuuaa agaucuucuu aucaacagcu 8640
uaaaaauuag ccaguauaua cugaacaucc acuguauaaa aagcacauua uggggugcuc 8700
caguagguac agcagugauc gagacagaau cauagccuuc agggaagagg uauaugcaau 8760
guucucuccu uccaaagauu accuagauag agaacuguuc auaagaaaua ucuugguacu 8820
gucuacauua cucuugagau auaaaauaua uauuauuucu uacgucugaa augagucagu 8880
uguuucuaaa acaauuugua uuaaaguauu cacauuaaaa auuuguaaaa uacagaaaag 8940
uagagagaaa aaaucaugaa uuuuuaacau gguaaugauu auaucaguuu cguucuuggc 9000
guuucuuuaa cuugauggga uagcuaaugu uuuuugucau ugcauagcuu uguaaacuug 9060
uccuaaggau uauauaauuu cagcaugagu uaguuucuaa guaugucaga aaucuagcuu 9120
uuuuguggua auuguuguuu uacacaaaau gauuaauaaa agacucuaaa cuaaccuugg 9180
cuuuagaaau gcuuuuuaaa uuuuaaaaua gugaaugagu agcagauuac uuucuaguau 9240
uucuuuaagg ucaccaaaau cacuuaacuu gcuuaaaaua uugauggaaa uaucaacuac 9300
guacaguuga ccuaaauuag aaaugggugu uuuuuaaaua gugaaauuua uaaauauaau 9360
auguauauuu uaaaauacag uuuauauuau agaguuaugu uccucuguaa uaauuucucu 9420
uuacacugaa ucauguucag uuuuuauuau gcagauaauu uaaucuuaca gcuuugaucu 9480
uuuuuaaaaa auaaaacagc cauuuggagu cuaaa 9515
<210> 2
<211> 20
<212> DNA
<213>reference gene GAPDH specific PCR forward primer
<400> 2
accacagtcc atgccatcac 20
<210> 3
<211> 20
<212> DNA
<213>reference gene GAPDH specific PCR reverse primer
<400> 3
tccaccaccc tgttgctgta 20
<210> 4
<211> 20
<212> DNA
<213>LINC00472 forward primer
<400> 4
gcatctgtca acgctcctct 20
<210> 5
<211> 20
<212> DNA
<213>LINC00472 reverse primer
<400> 5
ccgcgttctt tgtgtgtctc 20
<210> 6
<211> 30
<212> DNA
<213>in situ hybridization detects LINC00472 probe 1
<400> 6
caaaactagg attctgtctt tgaggcagac 30
<210> 7
<211> 30
<212> DNA
<213>in situ hybridization detects LINC00472 probe 2
<400> 7
aagaatggaa gtgggaagag agaaagactt 30
<210> 8
<211> 30
<212> DNA
<213>in situ hybridization detects LINC00472 probe 3
<400> 8
taattcaggg gtatccgtct tagtttaggc 30
<210> 9
<211> 30
<212> DNA
<213>GAPDH probe 1
<400> 9
ccactttacc agagttaaaa gcagccctgg 30
<210> 10
<211> 30
<212> DNA
<213>GAPDH probe 2
<400> 10
gtcagaggag accacctggt gctcagtgta 30
<210> 11
<211> 30
<212> DNA
<213>GAPDH probe 3
<400> 11
cagtagaggc agggatgatg ttctggagag 30
Claims (5)
1. detecting the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity, which is characterized in that
The reagent is used to prepare mouth neoplasm auxiliary diagnosis or outcome prediction preparation, long-chain non-coding RNA LINC00472
Sequence see SEQ NO:1.
2. application according to claim 1, which is characterized in that the mouth neoplasm auxiliary diagnosis or outcome prediction system
Agent is that the expression according to long-chain non-coding RNA LINC00472 in mouth neoplasm is pre- to carry out auxiliary diagnosis and curative effect
It surveys, LINC00472 expression is significant in mouth neoplasm tissue lowers.
3. application according to claim 1, which is characterized in that the mouth neoplasm auxiliary diagnosis or outcome prediction system
Agent is real time fluorescent quantitative detection reagent.
4. application according to claim 1, which is characterized in that include in the real time fluorescent quantitative detection reagent
Primer sequence for real time fluorescent quantitative detection LINC00472 expression:
Forward primer: 5 '-GCATCTGTCAACGCTCCTCT-3 ',
Reverse primer: 5 '-CCGCGTTCTTTGTGTGTCTC-3 '.
5. application according to claim 3 or 4, which is characterized in that the real time fluorescent quantitative detection preparation includes:
Reference gene GAPDH Specific PCR primers:
Forward primer 5 '-ACCACAGTCCATGCCATCAC-3 '
Reverse primer 5 '-TCCACCACCCTGTTGCTGTA-3 '.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710076508.3A CN106701990B (en) | 2017-02-13 | 2017-02-13 | Detect the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710076508.3A CN106701990B (en) | 2017-02-13 | 2017-02-13 | Detect the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106701990A CN106701990A (en) | 2017-05-24 |
CN106701990B true CN106701990B (en) | 2019-04-09 |
Family
ID=58910820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710076508.3A Active CN106701990B (en) | 2017-02-13 | 2017-02-13 | Detect the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106701990B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015154715A1 (en) * | 2014-04-11 | 2015-10-15 | Anpac Bio-Medical Science (Lishui) Co., Ltd. | A method of diagnosis, prognosis or treatment of a cancer |
-
2017
- 2017-02-13 CN CN201710076508.3A patent/CN106701990B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015154715A1 (en) * | 2014-04-11 | 2015-10-15 | Anpac Bio-Medical Science (Lishui) Co., Ltd. | A method of diagnosis, prognosis or treatment of a cancer |
Non-Patent Citations (4)
Title |
---|
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer;Yuanyuan Fu et al;《Gynecologic Oncology》;20160923;第143卷;第642-649页 |
NR_026807.2;Anonymous;《GenBank》;20160612;第1-4页 |
Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer;Yi Shen et al;《Oncotarget》;20150325;第6卷(第11期);第8579-8592页 |
白介素1受体II mRNA在小鼠子宫蜕膜中的转录;于永生等;《吉林农业大学学报》;20131231;第35卷(第1期);第72-75页 |
Also Published As
Publication number | Publication date |
---|---|
CN106701990A (en) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105441581B (en) | Detect the application of the reagent of long-chain non-coding RNA LOC284454 expression quantity in tongue cancer | |
CN103074441B (en) | Application method of long-chain non-coding RNA (Ribonucleic Acid) gene LINC00312 | |
CN104388543B (en) | In situ hybridization probe, reagent and application of long non-coding RNA LOC401317 | |
CN104878011B (en) | Applications of the long-chain non-coding RNA AFAP1-AS1 on preparing breast cancer real time fluorescent quantitative auxiliary diagnosis preparation | |
CN105200152B (en) | Applications of the long-chain non-coding RNA LOC553103 on nasopharyngeal carcinoma prognosis preparation is prepared | |
CN106492228B (en) | The application of the siRNA of long-chain non-coding RNA LINC00673 and inhibitory preparation | |
CN104878010B (en) | Applications of the long-chain non-coding RNA AFAP1-AS1 on preparing Computer-aided Diagnosis of Breast Cancer and Index for diagnosis preparation | |
CN106480196B (en) | A kind of application of long-chain non-coding RNA LINC00152 | |
CN106701990B (en) | Detect the application of the reagent of long-chain non-coding RNA LINC00472 expression quantity in the tumor tissues of oral cavity | |
CN106319044B (en) | Biomarker and its application of a kind of nasopharyngeal carcinoma auxiliary diagnosis or outcome prediction | |
CN105200156B (en) | Long-chain non-coding RNA LOC553103 application | |
CN106884046B (en) | In situ hybridization detects the application of long-chain non-coding RNA LINC00472 reagent in the tumor tissues of oral cavity | |
CN106381339B (en) | The application process of long-chain non-coding RNA LINC00152 in situ hybridization probes | |
CN105506157B (en) | In situ hybridization detects the application of long-chain non-coding RNA LOC284454 reagent in tongue cancer | |
CN106511368B (en) | The application of the siRNA of long-chain non-coding RNA LINC00152 and inhibitory preparation | |
CN104388542B (en) | The application process of long-chain non-coding RNA LOC401317 in situ hybridization probe | |
CN106337084B (en) | The in situ hybridization detection reagent and its application of long-chain non-coding RNA LINC01420 | |
CN106636339B (en) | The application process of long-chain non-coding RNA LINC00673 in situ hybridization probes | |
CN108624678A (en) | A kind of biomarker for preeclampsia diagnosis and treatment | |
CN105267987B (en) | Applications of the long-chain non-coding RNA LOC553103 on stomach cancer cell inhibitor is prepared | |
CN106480030B (en) | The application of long-chain non-coding RNA LINC00673 | |
CN104328172B (en) | The application process of long-chain non-coding RNA LOC401317 primer | |
CN106309468B (en) | The application of the siRNA of long-chain non-coding LINC01420 and inhibitory preparation | |
CN105288656B (en) | Applications of the microRNA BART6-3p of Epstein-Barr virus coding on preparing nasopharyngeal carcinoma cell inhibitor | |
CN106755517B (en) | The application method of long-chain non-coding RNA LINC00472 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |